Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: EGFRvIII Clear all
Completed No phase listed Observational

Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies

NCT02666248
View directory record Official record
Conditions
Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Not yet recruiting Phase 1 Interventional

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208
View directory record Official record
Conditions
Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions
NK Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT07326566
View directory record Official record
Conditions
Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions
silevertinib in combination with temozolomide, temozolomide (TMZ)
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Springdale, Arkansas • Los Angeles, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1 Interventional

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

NCT00023634
View directory record Official record
Conditions
Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
Interventions
KLH, GMCSF
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
13
States / cities
Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

AMG 595 First-in-Human in Recurrent Gliomas

NCT01475006
View directory record Official record
Conditions
Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
Interventions
AMG 595
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBM
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

NCT01454596
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
Interventions
Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

CART-EGFRvIII + Pembrolizumab in GBM

NCT03726515
View directory record Official record
Conditions
Glioblastoma
Interventions
CART-EGFRvIII T cells, Pembrolizumab
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

NCT01238237
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), ANAPLASTIC ASTROCYTOMA (AOA), GBM, Anaplastic Astrocytoma
Interventions
Superselective Intraarterial Cerebral Infusion of Cetuximab
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

NCT00458601
View directory record Official record
Conditions
Malignant Glioma
Interventions
CDX-110 with GM-CSF, Temozolomide
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
34
States / cities
Orange, California • San Francisco, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 3 Interventional

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

NCT01480479
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Interventions
Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1 Interventional Results available

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

NCT03296696
View directory record Official record
Conditions
Glioblastoma or Malignant Glioma
Interventions
AMG 596, AMG 404
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1 Interventional

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

NCT03283631
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
EGFRvIII-CARs
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

Phase I Study of Safety and Immunogenicity of ADU-623

NCT01967758
View directory record Official record
Conditions
Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions
Cohort 1, Cohort 2, Cohort 3, Antibiotics
Biological · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1 Interventional

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

NCT02209376
View directory record Official record
Conditions
Patients With Residual or Reccurent EGFRvIII+ Glioma
Interventions
CART-EGFRvIII T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00643097
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
PEP-3 vaccine, sargramostim, Temozolomide
Biological · Drug
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1 Interventional Results available

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma

NCT02664363
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
EGFRvIII CAR T cells
Biological
Lead sponsor
Daniel Landi
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Not yet recruiting Phase 1 Interventional

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

NCT04903795
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma, Recurrent Glioblastoma
Interventions
hEGFRvIII-CD3 (BRiTE)
Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 4:00 PM EDT